Summary Dyadic International Inc (Dyadic) is a biotechnology company that discovers, develops, manufactures and commercializes protein-based drugs. The company utilizes its patented and proprietary technology Myceliopthora thermophila (C1) expression system, to conduct research and produce industrial enzymes. It also provides biologic vaccine and drug development services. Dyadic works in partnership with pharmaceutical company to develop imperative non-glycosylated therapeutic products such as insulin and ranibizumab with the help of C1 technology. The company caters to bioenergy, biopharmaceutical, biochemical and industrial enzyme industries. It operates through its laboratories and subsidiaries in the US and the Netherlands. Dyadic is headquartered in Jupiter, Florida, the US. Dyadic International Inc (DYAI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their... Research Beam Model: Research Beam Product ID: 2032771 250 USD New
Dyadic International Inc (DYAI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
 
 

Dyadic International Inc (DYAI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • Category : Pharmaceuticals
  • Published On : August   2017
  • Pages : 34
  • Publisher : GlobalData
 
 
 
Summary

Dyadic International Inc (Dyadic) is a biotechnology company that discovers, develops, manufactures and commercializes protein-based drugs. The company utilizes its patented and proprietary technology Myceliopthora thermophila (C1) expression system, to conduct research and produce industrial enzymes. It also provides biologic vaccine and drug development services. Dyadic works in partnership with pharmaceutical company to develop imperative non-glycosylated therapeutic products such as insulin and ranibizumab with the help of C1 technology. The company caters to bioenergy, biopharmaceutical, biochemical and industrial enzyme industries. It operates through its laboratories and subsidiaries in the US and the Netherlands. Dyadic is headquartered in Jupiter, Florida, the US.

Dyadic International Inc (DYAI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Dyadic International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Dyadic International Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Dyadic International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Dyadic International Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 8
Dyadic International Inc, Pharmaceuticals & Healthcare, Deal Details 9
Partnerships 9
Dyadic International Enters into R&D Agreement with BDI Holdings 9
Dyadic International Enters into Co-Development Agreement for C1 Technology 10
Licensing Agreements 11
BASF Enters Into Licensing Agreement With Dyadic International For C1 Technology 11
Dyadic International Inc - Key Competitors 12
Dyadic International Inc - Key Employees 13
Dyadic International Inc - Locations And Subsidiaries 14
Head Office 14
Other Locations & Subsidiaries 14
Recent Developments 15
Financial Announcements 15
Aug 10, 2017: Dyadic International Reports Second Quarter 2017 Financial Results 15
May 11, 2017: Dyadic International Reports First Quarter 2017 Financial Results 17
Mar 15, 2017: Dyadic International Reports 2016 Financial Results 19
Nov 10, 2016: Dyadic International Reports Third Quarter 2016 Financial Results 21
Aug 11, 2016: Dyadic International Reports Second Quarter 2016 Financial Results 23
May 12, 2016: Dyadic International Reports First Quarter 2016 Financial Results 25
Mar 29, 2016: Dyadic International Reports 2015 Annual Financial Results 27
Corporate Communications 29
Apr 06, 2017: Dyadic Announces Director Resignation 29
Aug 16, 2016: Dyadic International Appoints Arindam Bose, Ph.D., Distinguished Life Sciences Executive, to Board of Directors 30
Jan 19, 2016: Dyadic Announces Robert Burke Resignation 31
Legal and Regulatory 32
Apr 06, 2016: Dyadic International Announces it has Reached a Settlement with One of the Two Remaining Defendant Law Firms in its Professional Liability Litigation 32
Mar 03, 2016: Dyadic International Announces a January 6, 2017 Trial Date for Litigation Against Former Professional Services Providers 33
Appendix 34
Methodology 34
About GlobalData 34
Contact Us 34
Disclaimer 34

List of Tables
Dyadic International Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 2
Dyadic International Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 2
Dyadic International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Dyadic International Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Dyadic International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Dyadic International Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 8
Dyadic International Enters into R&D Agreement with BDI Holdings 9
Dyadic International Enters into Co-Development Agreement for C1 Technology 10
BASF Enters Into Licensing Agreement With Dyadic International For C1 Technology 11
Dyadic International Inc, Key Competitors 12
Dyadic International Inc, Key Employees 13
Dyadic International Inc, Subsidiaries 14
List of Figures
Dyadic International Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2
Dyadic International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2
Dyadic International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2
Dyadic International Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Dyadic International Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6
Dyadic International Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
PURCHASE OPTIONS
 
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter